SCHEMBL2024876

SCHEMBL2024876

CC1(C)CC(C(=O)NCCN=C=S)C(C)(C)N1O

nearest known ligand 0.40

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 6/20 0.40
NFE2L2 Q16236 6/20 0.40
GAA P10253 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SLC2A1 P11166 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2030480 0.88 KEAP1 (0.39) KEAP1NFE2L2SLC2A1
SCHEMBL28625375 0.86 KEAP1 (0.38) KEAP1NFE2L2SLC2A1
SCHEMBL8670419 0.81 KEAP1 (0.46) KEAP1NFE2L2
SCHEMBL23784774 0.78 GAA (0.40) GAAL3MBTL1
SCHEMBL22315409 0.78 L3MBTL1 (0.40) GAAL3MBTL1
SCHEMBL21103465 0.78 GAA (0.40) GAAL3MBTL1
SCHEMBL8411554 0.77 KEAP1 (0.35) KEAP1NFE2L2
SCHEMBL18545712 0.77 GAA (0.39) GAAL3MBTL1
SCHEMBL12846024 0.76 GAA (0.41) GAAL3MBTL1
SCHEMBL18545640 0.76 FPR3 (0.40) GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10881748-B2 Nitroxide containing amyloid binding agents for imaging and therapeutic uses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-01-05 US disclosed
US-10478513-B2 Nitroxide containing amyloid binding agents for imaging and therapeutic uses THE REGENTS OF THE UNIVERSITY OF CALIFONIA (US) 2019-11-19 US disclosed
US-20180221514-A1 NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2018-08-09 US disclosed
US-9580527-B2 Dual cure composite resins containing uretdione and unsaturated sites COVESTRO LLC (US) 2017-02-28 US disclosed
US-20160200857-A1 DUAL CURE COMPOSITE RESINS CONTAINING URETDIONE AND UNSATURATED SITES COVESTRO LLC 2016-07-14 US disclosed
US-9175117-B2 Dual cure composite resins containing uretdione and unsaturated sites COVESTRO LLC (US) 2015-11-03 US disclosed
US-9102866-B2 Radical trap in oil and gas stimulation operations ARKEMA INC. (US) 2015-08-11 US disclosed
WO-2014150712-A1 DUAL CURE COMPOSITE RESINS CONTAINING URETDIONE AND USATURATED SITES BAYER MATERIAL SCIENCE LLC (US) 2014-09-25 WO disclosed
US-20140275345-A1 DUAL CURE COMPOSITE RESINS CONTAINING URETDIONE AND USATURATED SITES COVESTRO LLC 2014-09-18 US disclosed
US-20120241158-A1 RADICAL TRAP IN OIL AND GAS STIMULATION OPERATIONS ARKEMA INC. (US) 2012-09-27 US disclosed
WO-2011071797-A1 RADICAL TRAP IN OIL AND GAS STIMULATION OPERATIONS ARKEMA INC. (US) 2011-06-16 WO disclosed
EP-0661309-A2 Cyclo-olefin copolymers and process for their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1995-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881748-B2 Nitroxide containing amyloid binding agents for imaging and therapeutic uses APP, APBA1, CRYAB KEAP1 338/4885NFE2L2 434/4885GAA 1175/4885
US-10478513-B2 Nitroxide containing amyloid binding agents for imaging and therapeutic uses APP, APBA1, CRYAB KEAP1 338/4885NFE2L2 434/4885GAA 1175/4885
US-20180221514-A1 NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES APP, APBA1, CRYAB KEAP1 348/4885NFE2L2 443/4885GAA 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.